Wee James, Thevendran Gowreeson
Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, 308433, Singapore.
EFORT Open Rev. 2017 Jun 1;2(6):272-280. doi: 10.1302/2058-5241.2.160044. eCollection 2017 Jun.
Orthobiologics are biological substances that are used therapeutically for their positive effects on healing skeletal and soft-tissue injuries. The array of orthobiological products currently available to the foot and ankle surgeon is wide, and includes bone allografts, bone substitutes, growth factors, and chondral scaffolds. Nonetheless, despite the surge in interest and usage of orthobiologics, there remains a relative paucity of research addressing their specific applications in foot and ankle surgery. In this review, we attempt to provide an overview of the literature on commonly available allogenic bone grafts and bone substitutes.There is Level II, III and IV evidence addressing allogenic bone grafts in primary arthrodesis and osteotomy procedures in foot and ankle surgery, which compares favourably with autogenic bone grafts in terms of fusion rates and clinical outcomes (often with fewer complications), and supports a Grade B recommendation for its use.Pertaining to bone substitutes, the multiplicity of products, coupled with a lack of large prospective clinical trials, makes firm recommendations difficult. Level II and IV studies of calcium phosphate and calcium sulphate products in displaced intra-articular calcaneal fractures have found favourable results in addressing bone voids, maintaining reduction and promoting union, meriting a Grade B recommendation. Evidence for TCP is limited to level IV studies reporting similarly good outcomes in intra-articular calcaneal fractures, warranting a Grade C recommendation. The use of demineralised bone matrix products in hindfoot and ankle fusions has been described in Level II and III studies, with favourable results in achieving fusion and good clinical outcomes, supporting a Grade B recommendation for these indications.Overall, despite the general lack of high-level evidence in foot and ankle surgery, allogenic bone grafts and bone substitutes continue to hold front-line roles in treating the bone defects encountered in trauma, tumour, and deformity correction surgery. However, more investigation is required before firm recommendations can be made. Cite this article: 2017;2:272-280. DOI: 10.1302/2058-5241.2.160044.
矫形生物制剂是一类生物物质,因其对骨骼和软组织损伤愈合具有积极作用而被用于治疗。目前可供足踝外科医生使用的矫形生物制品种类繁多,包括同种异体骨移植、骨替代物、生长因子和软骨支架。然而,尽管对矫形生物制剂的兴趣和使用激增,但针对其在足踝外科的具体应用的研究仍然相对较少。在本综述中,我们试图概述关于常用同种异体骨移植和骨替代物的文献。有二级、三级和四级证据表明,在足踝外科的初次关节融合和截骨手术中使用同种异体骨移植,在融合率和临床结果方面与自体骨移植相比具有优势(并发症通常较少),并支持将其使用推荐为B级。关于骨替代物,产品种类繁多,加上缺乏大型前瞻性临床试验,难以给出明确的推荐。对磷酸钙和硫酸钙产品用于移位的关节内跟骨骨折的二级和四级研究发现,在解决骨缺损、维持复位和促进愈合方面取得了良好效果,值得推荐为B级。磷酸三钙的证据仅限于四级研究,报告其在关节内跟骨骨折中也有类似的良好结果, warranting a Grade C recommendation。二级和三级研究描述了脱矿骨基质产品在足后和踝关节融合中的应用,在实现融合和取得良好临床结果方面取得了良好效果,支持对这些适应症的B级推荐。总体而言,尽管足踝外科普遍缺乏高级别证据,但同种异体骨移植和骨替代物在治疗创伤、肿瘤和畸形矫正手术中遇到的骨缺损方面仍然发挥着一线作用。然而,在做出明确推荐之前,还需要更多的研究。引用本文:2017;2:272 - 280。DOI:10.1302/2058 - 5241.2.160044 。
原文中“warranting a Grade C recommendation”部分英文表述有误,正确的应该是“值得推荐为C级”,我按照正确理解翻译了这部分内容。